Valuation: Brooks Laboratories Limited

Market Cap 2.07B 21.35M 19.06M 17.73M 16.13M 30.46M 30.59M 213M 83.63M 1.05B 80.16M 78.4M 3.38B P/E 2025
-28.6x
P/E 2026 4.45x
Enterprise Value 2.08B 21.54M 19.23M 17.89M 16.27M 30.73M 30.86M 215M 84.38M 1.06B 80.87M 79.1M 3.41B EV / Sales 2025
3.93x
EV / Sales 2026 1.3x
Free-Float
45.16%
Yield 2025 *
-
Yield 2026 -
09-16 Brooks Laboratories Limited Announces Resignation of Krutika Rane as Company Secretary and Compliance Officer (Key Managerial Personnel), Effective October 9, 2026 CI
08-13 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
07-17 Brooks Laboratories Limited Announces Appointment of Rajesh Mahajan to President Trading and Senior Management Personnel, Effective July 17, 2026 CI
06-18 Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited for INR 1.1 billion. CI
05-29 Brooks Laboratories appoints Prashant Rathi as CEO RE
05-29 Brooks Laboratories names Prashant Rathi as CEO RE
05-29 Brooks Laboratories Limited Announces Appointment of Prashant Rathi as Chief Executive Officer, Effective June 1, 2026 CI
05-29 Brooks Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-06 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
25-10-16 Brooks Laboratories Limited Announces That Mr. Rajesh Mahajan Resigned as President - Procurement, with Effect from 16 October 2025 CI
25-08-13 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
25-05-28 Brooks Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
25-02-13 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
1 day-6.54%
1 week+20.83%
Current month+17.46%
1 month+3.88%
3 months-6.17%
6 months-8.49%
Current year-18.22%
1 week 54.3
Extreme 54.3
75.6
1 month 52.97
Extreme 52.97
75.6
Current year 36.3
Extreme 36.3
82.44
1 year 36.3
Extreme 36.3
130.98
3 years 36.3
Extreme 36.3
198.86
5 years 36.3
Extreme 36.3
198.86
10 years 13.85
Extreme 13.85
198.86
Manager TitleAgeSince
Chief Executive Officer 58 2002-01-22
Chief Executive Officer - 2026-05-31
President 58 2023-08-22
Director TitleAgeSince
Director/Board Member 62 2010-09-09
Director/Board Member 61 2011-09-12
Director/Board Member 53 2022-11-22
Change 5-day change 1-year change 3-year change Capi.($)
-6.54%+20.83%-48.84%-40.01% 21.35M
-0.01%+3.46%+44.34%+93.72% 1,051B
+0.50%+3.81%+37.54%+67.96% 630B
+1.01%+5.32%+21.54%+88.75% 489B
-0.30%+3.77%+68.97%+39.79% 359B
+0.70%+3.27%+24.20%+42.58% 344B
+0.54%+2.68%+14.45%+34.31% 272B
-0.39%+1.87%-5.82%+7.77% 246B
+0.19%+3.08%+42.06%+45.73% 224B
-0.73%+3.68%+26.85%+95.35% 187B
Average -0.50%+5.37%+22.53%+47.59% 380.37B
Weighted average by Cap. +0.25%+2.93%+34.40%+66.52%

Financials

2025 2026
Net sales 826M 8.53M 7.62M 7.09M 6.45M 12.17M 12.22M 85.3M 33.42M 421M 32.03M 31.33M 1.35B 857M 8.86M 7.91M 7.36M 6.69M 12.64M 12.7M 88.58M 34.71M 437M 33.27M 32.54M 1.4B
Net income -99.67M -1.03M -920K -856K -778K -1.47M -1.48M -10.3M -4.03M -50.81M -3.87M -3.78M -163M 246M 2.54M 2.27M 2.11M 1.92M 3.62M 3.64M 25.4M 9.95M 125M 9.54M 9.33M 402M
Net Debt 75.39M 779K 696K 647K 589K 1.11M 1.12M 7.79M 3.05M 38.44M 2.93M 2.86M 123M 18.44M 191K 170K 158K 144K 272K 273K 1.9M 746K 9.4M 715K 700K 30.17M
Projected Income Statement - Annual - Brooks Laboratories Limited
Logo Brooks Laboratories Limited
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company. The Company specializes in supplying pharmaceutical products to government bodies, healthcare institutions, and large organizations. It operates through two segments, which include manufacturing and trading. The manufacturing segment comprises its own manufacturing operations and loan-licensing business relating to pharmaceutical products, ingredients, and intermediaries. The trading segment comprises principal-to-principal trading activities in pharmaceutical products, ingredients, and intermediaries. Its General Products offerings include Liquid Injection (Ampoules), Liquid Injection (Vials), Dry Powder Injections (Vials), Lyophilised Injections, Eye/Ear Drops, and Nasal Drops. The Company's Critical Care Division (CCD), operates through a robust distribution network, delivering injectables to hospitals and healthcare institutions across India.
Employees
347
Date Price Change Volume
26-10-12 ₹65.54 -6.54% 160,788
26-10-09 ₹70.13 +0.96% 1,060,555
26-10-08 ₹69.46 +18.17% 1,508,771
26-10-07 ₹58.78 -1.48% 79,202
26-10-06 ₹59.66 +9.99% 58,724
  1. Stock Market
  2. Stocks
  3. BROOKS Stock